Lupus nephritis – An update on disparities affecting african americans

Gilda M. Portalatin, Surafel K. Gebreselassie, Shane A. Bobart

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations

Abstract

Lupus Nephritis is a complex clinical manifestation of systemic lupus erythematosus (SLE) associated with significant morbidity and mortality. It disproportionately affects minorities, especially African Americans (AA) with higher rates of progression to end stage kidney disease. Several factors are implicated including genetic predisposition to both SLE and chronic kidney disease, social determinants of health such as income inequality, education disparities, social isolation/lack of support, health care access and affordability. Clinically, AA may have higher auto-antibody titers, including several antibodies occurring simultaneously. AA are more prone to severe disease such as Class III and IV lupus nephritis. Fortunately, clinical trials have shown a favorable benefit/response among African Americans to mycophenolate mofetil. However, newer and alternative agents such as Rituximab, Belimumab and Voclosporin are widely unaffordable, and AA remain underrepresented in these clinical trials. The current state of disparities affecting LN patients of AA ancestry is a call for better access to healthcare and social support systems, greater inclusion/representation in clinical trials, and making new and alternative regimens more affordable and cost effective.

Original languageEnglish (US)
Pages (from-to)S34-S42
JournalJournal of the National Medical Association
Volume114
Issue number3
DOIs
StatePublished - Jun 2022

Keywords

  • African american
  • Disparities
  • Lupus nephritis
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Lupus nephritis – An update on disparities affecting african americans'. Together they form a unique fingerprint.

Cite this